Sleep apnea is a condition in which breathing is repeatedly paused while sleeping, causing the body to wake up in order to resume breathing. Sleep apnea most commonly occurs when the airway becomes blocked or collapses, known as obstructive sleep apnea (OSA), or when the brain fails to signal to the rest of the body to breathe, known as central sleep apnea.  While it is often framed as a sleep disorder, growing evidence confirms it is a systemic condition with widespread metabolic, cardiovascular, neurologic, and mental health consequences. Despite its prevalence, OSA remains significantly underdiagnosed. Community and health-system pharmacists can serve an important role to help identify high-risk patients, initiate screening, and support long-term treatment success. This article highlights what pharmacists need to know to recognize sleep apnea in everyday practice — often hiding in plain sight. 

 

Why Sleep Apnea Is More Than a Sleep Disorder 

OSA is characterized by repeated upper airway collapse during sleep, leading to intermittent hypoxia, sleep fragmentation, and sympathetic nervous system activation. Over time, these physiological stressors drive metabolic dysfunction, cardiovascular disease, and neurocognitive impairment, even in patients who do not fit the stereotypical profile. 

Importantly, many patients with OSA present not with sleep complaints, but with hypertension, mood disorders, headaches, weight gain, or medication resistance — conditions pharmacists manage daily. 

 

Treatment Options: Masks, Devices, and Newer Technologies 

Positive Airway Pressure (PAP) Therapy 

Continuous Positive Airway Pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) devices remain first-line therapy for moderate to severe OSA. These machines deliver a stream of pressurized air through a mask, which acts as an air splint to keep the throat open during sleep. CPAP devices deliver a single constant pressure throughout the night, while BiPAP delivers a higher pressure when breathing in and lower one for breathing out. However, the most common barrier to success with PAP therapy is adherence — often driven by mask discomfort rather than pressure settings. 

 

Mask Types: Pros & Cons 

Full-Face Masks (covers the nose/mouth) 

  • Pros:Ideal for mouth breathers or nasal obstruction, supports higher pressures 
  • Cons:Higher leak rates, skin irritation, claustrophobia, uncomfortable for side-sleeping 

Nasal Masks (covers nose) 

  • Pros:Improved comfort and seal for many patients 
  • Cons:Ineffective for chronic congestion/ mouth breathing, pressure sores on nose bridge 

Nasal Pillow Masks (sits at nostril) 

  • Pros:Minimal facial contact, often higher acceptance 
  • Cons:Nasal dryness, uncomfortable at higher pressure, ineffective for mouth breathers 

 

Adaptive Servo-Ventilation (ASV) 

ASV is a non-invasive PAP therapy for less common forms of sleep apnea, including central, complex, and opioid-induced breathing issues. ASV adjusts pressure automatically on a breath-by-breath basis. The SERVE-HF trail showed significantly higher risk of cardiovascular death in patients using ASV with systolic heart failure, making this treatment contraindicated in many heart failure patients because the positive pressure from ASV may trigger arrhythmias and reduce cardiac output. 

 

Newer & Alternative Devices 

Auto-adjusting PAP systems: These machines adjust on a breath-by-breath basis to reduce pressure when unneeded, often by tracking sleep data. They are ideal for patients whose needs change due to sleep position or alcohol consumption. 

Oral appliance therapy: These custom-made removable devices fitted by a dentist look like mouthguards and are less intrusive than CPAP for more mild cases. They work by pushing the jaw forward or using suction to keep the tongue forward. 

Positional therapy devices: These specialized garments, belts, or pillows help prevent patients from sleeping on their backs, when more severe symptoms occur. Some devices use gentle vibration or physical barriers to promote side-sleeping while often tracking sleep data and may be used in conjunction with CPAP therapy or as an alternative for patients with mask discomfort.  

Hypoglossal nerve stimulation: These implanted medical devices are an alternative for select patients unable to tolerate PAP. They create mild electrical stimulation to the hypoglossal nerve to move the tongue forward and open the airway. 

 

Pharmacists can help patients understand options and normalize the need for reassessment if therapy is failing. 

 

Whole-Body Consequences of Undiagnosed or Untreated Sleep Apnea 

Metabolic Effects 

  • Insulin resistance and impaired glucose tolerance
  • Worsening glycemic control in patients with diabetes
  • Weight gain driven by leptin and ghrelin dysregulation
  • Increased cardiometabolic risk independent of BMI

Cardiovascular Effects 

  • Resistant hypertension (often requiring ≥3 agents)
  • Atrial fibrillation and other cardiac arrhythmias 
  • Increased risk of myocardial infarction and stroke
  • Nocturnal blood pressure non-dipping

Neurologic & Mental Health Effects 

  • Daily morning headache sdue to nocturnal hypoxia and CO₂ retention 
  • Brain fog, impaired memory, and reduced executive function
  • Depression, anxiety, irritability, and emotional dysregulation
  • Increased risk of motor vehicle and workplace accidents

Hormonal & Inflammatory Impact 

  • Chronically elevated cortisol
  • Reduced testosterone levels
  • Persistent low-grade systemic inflammation

 

High-Yield Red Flags Pharmacists Can Identify at the Counter

Pharmacists should consider sleep apnea risk when patients report or demonstrate: 

  • Waking with headaches every morning
  • Loud snoring or witnessed apneas (reported by a partner)
  • Excessive daytime sleepiness despite adequate time in bed
  • Falling asleep while reading, watching TV, or driving
  • Poorly controlled or resistant hypertension
  • New or worsening depression or anxiety
  • Frequent nocturia
  • Nighttime GERD symptoms
  • Chronic fatigue mislabeled as “stress” or “burnout”
  • Regular use of sedatives, opioids, or alcohol at night

 

These signs often emerge during routine counseling — offering a natural opportunity for intervention. 

 

Quick Screening Tool: STOP-BANG in Community Pharmacy 

The STOP-BANG questionnaire is a validated, easy-to-use screening tool using yes/no responses, making it suitable for pharmacy settings to determine if patients may be at risk for Obstructive Sleep Apnea. 

STOP-BANG Components 

  • Snoring
  • Tiredness during daytime
  • Observed apneas
  • Pressure (hypertension)
  • BMI >35 kg/m²
  • Age >50 years
  • Neck circumference >40 cm
  • Gender (male)

Interpretation 

  • Score ≥3: Increased risk of OSA
  • Score ≥5, or≥2 for males or patients with BMI.35kg/m2: High risk; referral strongly recommended

Pharmacist Tip: Introduce screening during medication therapy reviews, hypertension counseling, or diabetes check-ins with language such as: “Many people with resistant blood pressure or morning headaches have undiagnosed sleep apnea — would you like to do a quick screening?” 

 

Medication-Related Contributors Pharmacists Should Watch For 

Certain medications can cause relaxation of the throat muscles causing airway collapse or may suppress protective arousal responses: 

  • Benzodiazepines and Z-hypnotics
  • Opioids
  • Muscle relaxants
  • Alcohol (especially evening use)
  • Medications that induce weight gain, such as corticosteroids or mood stabilizers 
  • Chronic nasal congestion contributors (sedating antihistamines vs intranasal steroids)

Medication optimization can significantly improve sleep apnea severity and treatment tolerance. 

Guideline Updates in Late 2025: What Pharmacists Should Know 

In late 2025, the American Academy of Sleep Medicine (AASM) released a series of updated clinical practice guidelines and recommendations that refine how clinicians diagnose and manage sleep-disordered breathing — including obstructive and central sleep apnea. These updates emphasize individualized treatment choices, expand therapeutic options, and clarify care in special settings. 

Key changes affecting clinical practice: 

  • Refined treatment recommendations for Central Sleep Apnea: The new guidelines provide a broader set of evidence-based treatment options tailored to the underlying etiology of CSA, including CPAP, BiPAP with a backup rate, adaptive servo-ventilation (ASV), low-flow oxygen, oral acetazolamide, and transvenous phrenic nerve stimulation for select patients. ASV use is now conditionally recommended in specific cases but should be applied cautiously in patients with heart failure with reduced ejection fraction and monitored closely by experienced centers. 
  • Emphasis on continuing therapy in hospitalized adults: For patients admitted to the hospital with an established diagnosis of sleep-disordered breathing, the updated guidance recommends continued treatment (e.g., PAP therapy or approved alternatives such as oral appliance therapy or upper airway stimulation) unless contraindications exist, underscoring that acute hospitalization is not a reason to stop effective chronic therapy without clear clinical rationale. 
  • Integration with broader practice guidelines: Updated guidance encourages incorporating sleep apnea evaluation into the care of medically complex patients — particularly those with comorbid conditions — and highlights the role of screening, weight management, and referral pathways in multidisciplinary care. Parallel practice guidelines also emphasize weight management, behavioral therapies, and consideration of adjunctive pharmacotherapy for residual daytime sleepiness in optimally treated patients, reflecting a more holistic approach to sleep-related care. 

What this means for pharmacists: These updates reinforce the need to recognize both obstructive and central sleep apnea patterns, understand a wider array of therapeutic options, and support continuity of treatment in settings beyond outpatient sleep clinics. Pharmacists can play a key role in counseling patients about therapy continuation during acute care transitions, identifying those who may benefit from advanced treatments, and coordinating care with sleep specialists. 

 

Counseling Pearls to Improve Adherence 

  • Set expectations: adaptation to PAP therapy takes time 
  • Emphasize mask fit over pressure changes
  • Support nasal health and humidification
  • Normalize early frustration
  • Encourage follow-up if symptoms persist despite therapy
  • Offer education on wearable devices that track sleep and times patients experience nighttime waking 

Retail Pharmacy Opportunities & Revenue Tie-Ins 

  • Sleep apnea screening and referral programs
  • OTC bundles: nasal support, humidification, oral health
  • Sleep hygiene counseling services
  • Collaboration with sleep clinics and DME providers 
  • Hypertension and diabetes programs incorporating sleep assessment

Key Takeaways for Pharmacists 

  • Sleep apnea is a whole-body disorder, not just a sleep complaint
  • Morning headaches, mood changes, and resistant hypertension are key clues
  • Pharmacists are well-positioned to screen, educate, and refer patients to sleep specialists
  • Optimizing therapy improves outcomes far beyond sleep quality

References 

  1. Perez, K., Seifert, S., Shah, M., Patel, I., & Patel, S. (2025). 0639 Demographic, Clinical, and Treatment Characteristics in a Large Cohort of Patients Evaluated for Sleep Apnea. Sleep, 48(Supplement_1), A279-A279. https://doi.org/10.1093/sleep/zsaf090.0639 
  2. Martires, J., Ram, R., & Wallace, J. (2021). Introduction to Sleep-Disordered Breathing and Treatment., 509-528. https://doi.org/10.1093/med/9780190885403.003.0031 
  3. Cawley, M. and Warning, W. (2016). A systematic review of pharmacists performing obstructive sleep apnea screening services. International Journal of Clinical Pharmacy, 38(4), 752-760. https://doi.org/10.1007/s11096-016-0319-0 
  4. Fodor, A., Huțanu, D., Budin, C., Ianoși, M., Rachiș, D., Sárközi, H., … & Jimborean, G. (2025). Central Sleep Apnea in Adults: An Interdisciplinary Approach to Diagnosis and Management—A Narrative Review. Journal of Clinical Medicine, 14(7), 2369. https://doi.org/10.3390/jcm14072369 
  5. Huseini, T., McArdle, N., Jasper, E., Kurmagadda, S., Douglas, J., King, S., … & Singh, B. (2020). The use and effectiveness of adaptive servo ventilation in central sleep apnea: a study of consecutive sleep clinic patients. Journal of Sleep Research, 29(4). https://doi.org/10.1111/jsr.13016 
  6. Mager, N., Bright, D., Murphy, B., Rondon-Begazo, A., & Kelling, S. (2017). Opportunities for Pharmacists and Student Pharmacists to Provide Clinical Preventive Services. Innovations in Pharmacy, 8(1). https://doi.org/10.24926/21550417.1340 
  7. Pornsriniyom, D. (2014). Sleep Apnea: A Novel Risk Factor in Acute Stroke and Transient Ischemic Attack. The Bangkok Medical Journal, 07(01), 32-38. https://doi.org/10.31524/bkkmedj.2014.02.007 
  8. Marshall, N. S., Wong, K., Cullen, S. R., Knuiman, M., & Grunstein, R. R. (2014). Sleep Apnea and 20-Year Follow-Up for All-Cause Mortality, Stroke, and Cancer Incidence and 
  9. Mortality in the Busselton Health Study Cohort. Journal of Clinical Sleep Medicine, 10(04), 355-362. https://doi.org/10.5664/jcsm.3600 
  10. Testelmans, D., Tamisier, R., Barone‐Rochette, G., Baguet, J., Roux‐Lombard, P., Pépin, J., … & Lévy, P. (2013). Profile of circulating cytokines: Impact of OSA, obesity and acute cardiovascular events. Cytokine, 62(2), 210-216. https://doi.org/10.1016/j.cyto.2013.02.021 
  11. Scorza, F. A., Cavalheiro, É. A., Scorza, C. A., Galduróz, J. C. F., Tufik, S., & Andersen, M. L. (2013). Sleep Apnea and Inflammation – Getting a Good Night’s Sleep with Omega-3 Supplementation. Frontiers in Neurology, 4. https://doi.org/10.3389/fneur.2013.00193 
  12. Hopps, E. and Caimi, G. (2015). Obstructive Sleep Apnea Syndrome: Links Betwen Pathophysiology and Cardiovascular Complications. Clinical and Investigative Medicine, 38(6), E362-E370. https://doi.org/10.25011/cim.v38i6.26199 
  13. Seo, M. Y. and Lee, S. H. (2020). Compliance with Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnea. Sleep Medicine Research, 11(1), 7-14. https://doi.org/10.17241/smr.2020.00563 
  14. Battisha, A., Kahlon, A., & Kalra, D. (2025). Sleep-Disordered Breathing and Hypertension—A Systematic Review. Journal of Clinical Medicine, 14(9), 3115. https://doi.org/10.3390/jcm14093115 
  15. Kushida, C. A., Littner, M. R., Hirshkowitz, M., Morgenthaler, T. I., Alessi, C., Bailey, D. R., … & Wise, M. S. (2006). Practice Parameters for the Use of Continuous and Bilevel Positive Airway Pressure Devices to Treat Adult Patients With Sleep-Related Breathing Disorders. Sleep, 29(3), 375-380. https://doi.org/10.1093/sleep/29.3.375 
  16. Tovichien, P., Kulbun, A., & Udomittipong, K. (2022). Comparing Adherence of Continuous and Automatic Positive Airway Pressure (CPAP and APAP) in Obstructive Sleep Apnea (OSA) Children. Frontiers in Pediatrics, 10. https://doi.org/10.3389/fped.2022.841705 
  17. Pazarlı, A. C. and Esquinas, A. M. (2017). Intervention for CPAP adherence in OSAS: a choice to patient or technique?. Sleep and Breathing, 22(1), 55-55. https://doi.org/10.1007/s11325-017-1522-5